• Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.
    • Henderson V, Madrigal JM, Kendall LC, Parekh P, Newsome J, Chukwudozie IB, Comer-Hagans L, Coffey V, Grumbach G, Spencer S, Rodgers C, Kaur R, Balay L, Maga T, Ramamonjiarivelo Z, Balthazar C, Winn R, Watson K, Odoms-Young A, Hoskins KF.
    • BMC Health Serv Res. 2022 Jun 25;22(1):826. doi: 10.1186/s12913-022-08193-x.

    Identifier: NCT04082117: Uptake of Genetic Counseling Among African American Women. (ClinicalTrials.gov)

    • Stress, Anxiety, and Health-Related Quality of Life in BRCA1/2-Positive Women with and without Cancer: A Comparison of Four US Female Samples.
    • Dibble KE, Donorfio LKM, Britner PA, Bellizzi KM.
    • Gynecol Oncol Rep. 2022 Jun 20;101033. doi: 10.1016/j.gore.2022.101033.
    • Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system.
    • Knerr S, Guo B, Mittendorf KF, Spencer Feigelson H, Gilmore MJ, Jarvik GP, Kauffman TL, Keast E, Lynch FL, Muessig KR, Okuyama S, Veenstra DL, Zepp JM, Goddard KAB, Devine B.
    • Cancer. 2022 Jun 9. doi: 10.1002/cncr.34349. Epub ahead of print
    • Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK).
    • Loong L, Garrett A, Allen S, Choi S, Durkie M, Callaway A, Drummond J, Burghel GJ, Robinson R, Torr B, Berry IR, Wallace AJ, Eccles DM, Ellard S, Baple E, Evans DG, Woodward ER, Kulkarni A, Lalloo F, Tischkowitz M, Lucassen A, Hanson H, Turnbull C; CanVIG-UK.
    • Genet Med. 2022 Jun 3:S1098-3600(22)00757-2. doi: 10.1016/j.gim.2022.05.002. Epub ahead of print.
    • Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study.
    • Tiller JM, Cousens NE, Kaur R, Rowley S, Ko YA, Mahale S, Bankier A, Meiser B, Barlow-Stewart K, Burnett L, Jacobs C, James P, Trainer A, Neil S, Campbell IG, Andrews L, Delatycki M.
    • J Med Genet. 2022 Jun 3:jmedgenet-2022-108519. doi: 10.1136/jmedgenet-2022-108519. Epub ahead of print.
    • Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
    • Archer S, Fennell N, Colvin E, Laquindanum R, Mills M, Dennis R, Stutzin Donoso F, Gold R, Fan A, Downes K, Ford J, Antoniou AC, Kurian AW, Evans DG, Tischkowitz M.
    • Cancers (Basel). 2022 May 31;14(11):2716. doi: 10.3390/cancers14112716.
  • LitAlert ~~ GeneLit.com

    • Further validation of the Perceptions of Uncertainties in Genome Sequencing (PUGS) scale among patients with cancer undergoing tumor sequencing.
    • Umstead KL, Campbell R, Napier CE, Bartley N, Best MC, Butow PN, Biesecker BB.
    • Clin Genet. 2022 May 26. doi: 10.1111/cge.14169. Epub ahead of print.
    • Cancer patients’ understandings of genetic variants of uncertain significance in clinical care.
    • Amano Y, Raz A, Timmermans S, Shkedi-Rafid S.
    • J Community Genet. 2022 May 26. doi: 10.1007/s12687-022-00594-z. Epub ahead of print.
    • Use of a chatbot to increase uptake of cascade genetic testing.
    • Schmidlen T, Jones CL, Campbell-Salome G, McCormick CZ, Vanenkevort E, Sturm AC.
    • J Genet Couns. 2022 May 26. doi: 10.1002/jgc4.1592. Epub ahead of print.